Computed tomography-guided cryoablation in treating adrenal metastases: a retrospective single-center study.

IF 16.4 1区化学 Q1 CHEMISTRY, MULTIDISCIPLINARY

Accounts of Chemical Research Pub Date : 2024-10-21 DOI:10.4274/dir.2024.242956

Claudio Pusceddu, Eliodoro Faiella, Claudio Cau, Pierluigi Rinaldi, Luca Melis, Salvatore Marsico

{"title":"Computed tomography-guided cryoablation in treating adrenal metastases: a retrospective single-center study.","authors":"Claudio Pusceddu, Eliodoro Faiella, Claudio Cau, Pierluigi Rinaldi, Luca Melis, Salvatore Marsico","doi":"10.4274/dir.2024.242956","DOIUrl":null,"url":null,"abstract":"Purpose: To assess the effectiveness and safety of computed tomography (CT)-guided cryoablation for treating adrenal metastases (AMs).Methods: This study included 12 patients treated with 13 CT-guided cryoablation procedures for AMs between 2016 and 2020. Patients were selected based on specific criteria, including tumor size ≤5 cm and suitability for surgery. Procedures were performed by expert radiologists, with comprehensive monitoring for complications and regular post-treatment evaluations.Results: The primary technical success rate was 91.7%, with a secondary success rate of 100% following repeat procedures. Over an 8-24-month follow-up period, local tumor recurrence was observed in 16.7% of patients, and systemic progression occurred in five (41.6%) patients. The average overall survival duration was 26.4 ± 5.6 months.Conclusion: CT-guided cryoablation is a feasible and effective treatment option for AMs, demonstrating high technical success rates and manageable complications.Clinical significance: This study highlights CT-guided cryoablation as a promising treatment for AMs, offering a minimally invasive alternative to surgery with good local control and safety profile. Further research, including multi-center studies, is needed to confirm these findings.","PeriodicalId":1,"journal":{"name":"Accounts of Chemical Research","volume":null,"pages":null},"PeriodicalIF":16.4000,"publicationDate":"2024-10-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Accounts of Chemical Research","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.4274/dir.2024.242956","RegionNum":1,"RegionCategory":"化学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CHEMISTRY, MULTIDISCIPLINARY","Score":null,"Total":0}

引用次数: 0

Abstract

Purpose: To assess the effectiveness and safety of computed tomography (CT)-guided cryoablation for treating adrenal metastases (AMs).

Methods: This study included 12 patients treated with 13 CT-guided cryoablation procedures for AMs between 2016 and 2020. Patients were selected based on specific criteria, including tumor size ≤5 cm and suitability for surgery. Procedures were performed by expert radiologists, with comprehensive monitoring for complications and regular post-treatment evaluations.

Results: The primary technical success rate was 91.7%, with a secondary success rate of 100% following repeat procedures. Over an 8-24-month follow-up period, local tumor recurrence was observed in 16.7% of patients, and systemic progression occurred in five (41.6%) patients. The average overall survival duration was 26.4 ± 5.6 months.

Conclusion: CT-guided cryoablation is a feasible and effective treatment option for AMs, demonstrating high technical success rates and manageable complications.

Clinical significance: This study highlights CT-guided cryoablation as a promising treatment for AMs, offering a minimally invasive alternative to surgery with good local control and safety profile. Further research, including multi-center studies, is needed to confirm these findings.

查看原文本刊更多论文

计算机断层扫描引导下的冷冻消融治疗肾上腺转移瘤：一项回顾性单中心研究。

目的：评估计算机断层扫描（CT）引导下的冷冻消融术治疗肾上腺转移瘤（AMs）的有效性和安全性：本研究纳入了2016年至2020年间接受13次CT引导下冷冻消融术治疗肾上腺转移瘤的12名患者。患者的选择基于特定标准，包括肿瘤大小≤5厘米和是否适合手术。手术由放射科专家实施，并对并发症进行全面监测和定期进行治疗后评估：结果：初次技术成功率为91.7%，重复手术的二次成功率为100%。在8-24个月的随访期间，16.7%的患者出现局部肿瘤复发，5名患者（41.6%）出现全身性进展。平均总生存期为（26.4 ± 5.6）个月：临床意义：本研究强调了CT引导下冷冻消融术是一种治疗AMs的有前途的方法，它是手术的微创替代疗法，具有良好的局部控制和安全性。需要进一步的研究，包括多中心研究，来证实这些发现。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Accounts of Chemical Research 化学-化学综合

CiteScore

31.40

自引率

1.10%

发文量

312

审稿时长

2 months

期刊介绍： Accounts of Chemical Research presents short, concise and critical articles offering easy-to-read overviews of basic research and applications in all areas of chemistry and biochemistry. These short reviews focus on research from the author’s own laboratory and are designed to teach the reader about a research project. In addition, Accounts of Chemical Research publishes commentaries that give an informed opinion on a current research problem. Special Issues online are devoted to a single topic of unusual activity and significance. Accounts of Chemical Research replaces the traditional article abstract with an article "Conspectus." These entries synopsize the research affording the reader a closer look at the content and significance of an article. Through this provision of a more detailed description of the article contents, the Conspectus enhances the article's discoverability by search engines and the exposure for the research.